Ultragenyx’s employees were already braced for changes as the biopharma considered how to rebound from a pair of failed late-stage brittle bone disease trials.
- Home |
- Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans
Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans
- February 13, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
